228 related articles for article (PubMed ID: 21824412)
1. Differential expression of HIF-1α in CD44+CD24-/low breast ductal carcinomas.
Oliveira-Costa JP; Zanetti JS; Silveira GG; Soave DF; Oliveira LR; Zorgetto VA; Soares FA; Zucoloto S; Ribeiro-Silva A
Diagn Pathol; 2011 Aug; 6():73. PubMed ID: 21824412
[TBL] [Abstract][Full Text] [Related]
2. Gli1 is a potential cancer stem cell marker and predicts poor prognosis in ductal breast carcinoma.
Ni W; Yang Z; Qi W; Cui C; Cui Y; Xuan Y
Hum Pathol; 2017 Nov; 69():38-45. PubMed ID: 28965964
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic correlation of cancer stem cell markers CD44, CD24, VEGF and HIF-1α in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
Wang Z; Shi Q; Wang Z; Gu Y; Shen Y; Sun M; Deng M; Zhang H; Fang J; Zhang S; Xie F
Pathol Res Pract; 2011 Aug; 207(8):505-13. PubMed ID: 21802218
[TBL] [Abstract][Full Text] [Related]
4. CD44/CD24 immunophenotypes on clinicopathologic features of salivary glands malignant neoplasms.
Soave DF; Oliveira da Costa JP; da Silveira GG; Ianez RC; de Oliveira LR; Lourenço SV; Ribeiro-Silva A
Diagn Pathol; 2013 Feb; 8():29. PubMed ID: 23419168
[TBL] [Abstract][Full Text] [Related]
5. CD44/CD24 as potential prognostic markers in node-positive invasive ductal breast cancer patients treated with adjuvant chemotherapy.
Adamczyk A; Niemiec JA; Ambicka A; Mucha-Małecka A; Mituś J; Ryś J
J Mol Histol; 2014 Feb; 45(1):35-45. PubMed ID: 23835592
[TBL] [Abstract][Full Text] [Related]
6. Correlation between epidermal growth factor receptor and tumor stem cell markers CD44/CD24 and their relationship with prognosis in breast invasive ductal carcinoma.
Zheng Z; Shao N; Weng H; Li W; Zhang J; Zhang L; Yang L; Ye S
Med Oncol; 2015 Jan; 32(1):275. PubMed ID: 25429827
[TBL] [Abstract][Full Text] [Related]
7. Are CD44
Ryspayeva DE; Smolanka II; Dudnichenko АS; Lyashenko AA; Grinevich YA; Gurianov VG; Koshubarova MV; Seleznev AA
Exp Oncol; 2017 Sep; 39(3):224-228. PubMed ID: 28967636
[TBL] [Abstract][Full Text] [Related]
8. ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44+/CD24- phenotype.
Zhong Y; Shen S; Zhou Y; Mao F; Guan J; Lin Y; Xu Y; Sun Q
Med Oncol; 2014 Mar; 31(3):864. PubMed ID: 24519209
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularity.
Currie MJ; Beardsley BE; Harris GC; Gunningham SP; Dachs GU; Dijkstra B; Morrin HR; Wells JE; Robinson BA
Hum Pathol; 2013 Mar; 44(3):402-11. PubMed ID: 23036368
[TBL] [Abstract][Full Text] [Related]
10. Identification of glycoprotein markers for pancreatic cancer CD24+CD44+ stem-like cells using nano-LC-MS/MS and tissue microarray.
Zhu J; He J; Liu Y; Simeone DM; Lubman DM
J Proteome Res; 2012 Apr; 11(4):2272-81. PubMed ID: 22335271
[TBL] [Abstract][Full Text] [Related]
11. CD44+/CD24- cells and lymph node metastasis in stage I and II invasive ductal carcinoma of the breast.
Tiezzi DG; Valejo FA; Marana HR; Carrara HH; Benevides L; Antonio HM; Sicchieri RD; Milanezi CM; Silva JS; de Andrade JM
Med Oncol; 2012 Sep; 29(3):1479-85. PubMed ID: 21713550
[TBL] [Abstract][Full Text] [Related]
12. CD44+/CD24- phenotype contributes to malignant relapse following surgical resection and chemotherapy in patients with invasive ductal carcinoma.
Lin Y; Zhong Y; Guan H; Zhang X; Sun Q
J Exp Clin Cancer Res; 2012 Jul; 31(1):59. PubMed ID: 22762532
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of CD44 and CD24 for prognosis and chemotherapy response in invasive breast ductal carcinoma.
Chen Y; Song J; Jiang Y; Yu C; Ma Z
Int J Clin Exp Pathol; 2015; 8(9):11287-95. PubMed ID: 26617852
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of CD24 and claudin-7 immunoexpression in ductal invasive breast cancer.
Bernardi MA; Logullo AF; Pasini FS; Nonogaki S; Blumke C; Soares FA; Brentani MM
Oncol Rep; 2012 Jan; 27(1):28-38. PubMed ID: 21956537
[TBL] [Abstract][Full Text] [Related]
15. Molecular characterization of CD44
Da Cruz Paula A; Leitão C; Marques O; Rosa AM; Santos AH; Rêma A; de Fátima Faria M; Rocha A; Costa JL; Lima M; Lopes C
Virchows Arch; 2017 Mar; 470(3):311-322. PubMed ID: 28116522
[TBL] [Abstract][Full Text] [Related]
16. The role of tumor hypoxia in MUC1-positive breast carcinomas.
Zanetti JS; Soave DF; Oliveira-Costa JP; da Silveira GG; Ramalho LN; Garcia SB; Zucoloto S; Ribeiro-Silva A
Virchows Arch; 2011 Oct; 459(4):367-75. PubMed ID: 21892751
[TBL] [Abstract][Full Text] [Related]
17. The CD44+/CD24- phenotype relates to 'triple-negative' state and unfavorable prognosis in breast cancer patients.
Giatromanolaki A; Sivridis E; Fiska A; Koukourakis MI
Med Oncol; 2011 Sep; 28(3):745-52. PubMed ID: 20405247
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype.
Ricardo S; Vieira AF; Gerhard R; Leitão D; Pinto R; Cameselle-Teijeiro JF; Milanezi F; Schmitt F; Paredes J
J Clin Pathol; 2011 Nov; 64(11):937-46. PubMed ID: 21680574
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of putative cancer stem cell markers (CD24, CD44, CD133, and ALDH1) in human papillary thyroid carcinoma.
Han SA; Jang JH; Won KY; Lim SJ; Song JY
Pathol Res Pract; 2017 Aug; 213(8):956-963. PubMed ID: 28687160
[TBL] [Abstract][Full Text] [Related]
20. The role of CD44+/CD24-/low biomarker for screening, diagnosis and monitoring of breast cancer.
Camerlingo R; Ferraro GA; De Francesco F; Romano M; Nicoletti G; Di Bonito M; Rinaldo M; D'Andrea F; Pirozzi G
Oncol Rep; 2014 Mar; 31(3):1127-32. PubMed ID: 24366074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]